Cell and Tissue Research

, Volume 318, Issue 1, pp 261–273

Stem cell therapy for Parkinson’s disease: where do we stand?

  • Laurent Roybon
  • Nicolaj S. Christophersen
  • Patrik Brundin
  • Jia-Yi Li
Review

DOI: 10.1007/s00441-004-0946-y

Cite this article as:
Roybon, L., Christophersen, N.S., Brundin, P. et al. Cell Tissue Res (2004) 318: 261. doi:10.1007/s00441-004-0946-y

Abstract

A major neuropathological feature of Parkinson’s disease (PD) is the loss of nigrostriatal dopaminergic neuron. Patients exhibit motor symptoms, including bradykinesia, rigidity, and tremor. Neural grafting has been reported to restore striatial dopaminergic neurotransmission and induce symptomatic relief. The major limitation of cell replacement therapy for PD is the shortage of suitable donor tissue. The present review describes the possible sources of cells, including embryonic stem cells and somatic adult stem cells, both of which potentially could be used in cell therapy for PD, and discusses the advantages and disadvantages of each cell type.

Keywords

Parkinson’s diseaseNeural graftingEmbryonic stem cellsSomatic adult stem cells

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Laurent Roybon
    • 1
  • Nicolaj S. Christophersen
    • 1
  • Patrik Brundin
    • 1
  • Jia-Yi Li
    • 1
  1. 1.Section for Neuronal Survival, Wallenberg Neuroscience CenterLund UniversityLundSweden